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Abstract
Background: In 2019, of the 111 opioid deaths reported in the State of Vermont, 30 were found
to be prescription opioid-related and accidental. Medication Assisted Therapy (MAT) programs
are used to treat patients with substance use disorders, promoting recovery and preventing
overdose. Vermont uses the “Hub and Spoke” model to increase the availability of MAT for
patients with OUD by increasing the number of primary care providers who prescribe
buprenorphine. Hubs are the specialty opioid treatment programs while spokes are the officebased community settings where a patient receives ongoing follow up integrated into general
medical care. Evidence-based documentation guidelines and clinical quality measures exist to
improve the quality of care for these patients. Adherence to documentation guidelines at one
office-based spoke practice setting was unknown. Purpose: This project sought to evaluate
compliance to evidence-based documentation recommendations for patients being treated with
MAT through evaluation of provider documentation. Methods: A documentation evaluation tool
was created using the recommended American Academy of Addiction Psychiatry clinical quality
measures and evidence-based practice recommendations. A retrospective review of electronic
health record documentation was conducted to assess the presence or absence of 16
recommended quality measures within the provider clinical visit note. Results: Overall
documentation was compliant with evidence-based documentation recommendations in the
majority of documentation elements. A draft clinical progress note template with
recommendations for improvement was created. Conclusion: Participation in audit and feedback
of clinical records by providers may improve consistency of documentation and provide better
outcomes for patients with substance use disorder.
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Introduction
According to the Vermont Department of Health, opioid deaths slightly decreased from
130 in 2018 to 111 in 2019 (Vermont Department of Health, n.d.). Of these 111 deaths, 30 deaths
were deemed to be prescription opioid related and accidental (Vermont Department of Health,
n.d.). Valid prescribing/screening tools and evidence-based treatment guidelines are available to
guide providers in lowering prescription-opioid-related sequelae and eliminating accidental
deaths (American Academy of Addiction Psychiatry & Providers Clinical Support Systems, n.d.;
American Society of Addiction Medicine, 2020; Centers for Disease Control and Prevention,
2020; Dowell et al., 2016; Vermont Department of Health, n.d.). Medication Assisted Therapy
(MAT) programs are available to diagnose and treat patients with substance use disorders,
promoting recovery and preventing overdose.
Vermont currently uses the “Hub and Spoke” model to increase the availability of MAT
programs available to patients with opiate use disorder (OUD) by increasing the number of
primary care providers who prescribe buprenorphine (State of Vermont, 2022; Tanzman &
Nalley, 2020). Hubs are the specialty opioid treatment programs while spokes are the officebased setting where a patient is seen monthly or weekly for follow up. This system allows
patients who require intensive treatment to begin their treatment in a hub facility which offer
daily medication administration and support at the beginning of treatment. There are currently
nine hubs in Vermont for this model of treatment (Tanzman & Nalley, 2020). For patients
seeking ongoing treatment integrated into general medical care, the “spokes” provide ongoing
treatment options in a primary care setting (State of Vermont, 2022). This approach provides
ongoing treatment for the patient but requires specialized training for the primary care provider
(SAMSHA, 2022; Tanzman & Nalley, 2020). Federal statutes, regulations and clinical practice
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govern MAT for opioid addiction (SAMHSA, 2022). These guidelines require specialized
training before prescribing of pharmacological agents to assist with the treatment of opioid use
disorder as part of a comprehensive treatment plan (SAMHSA, 2022).
Medications such as methadone (Dolophine) and buprenorphine (Buprinex) are used for
treatment of OUD. Prescribing these medications require waivers and training for providers to
prescribe these medications in an office setting (SAMHSA, 2022). Methadone must be
administered daily in an opioid treatment facility, while buprenorphine may be prescribed on a
weekly or monthly basis for at-home use (SAMHSA, 2022). Methadone is considered to be a full
agonist as it completely occupies the mu-opioid receptor and decreases the painful symptoms of
opioid withdrawal. Methadone also simultaneously blocks the effect of other opioid drugs in the
system (SAMHSA, 2022). Methadone lasts 24–36 hours so that patients will not experience the
highs and lows that are common with heroin use. A 12-month treatment course is considered the
minimum duration for methadone maintenance (SAMHSA, 2022). Buprenorphine is a partial
agonist and does not completely occupy the mu-receptor, and it is commonly combined with
naloxone (Narcan) to form the drug Suboxone. The optimal duration of treatment is patientspecific, and decreasing the dosage involves a taper that spans several months (SAMHSA, 2022).
Patients attempting to stop using opioids are at an increased risk for overdose and relapse as the
body has lowered tolerance levels to opioid; so, treatment and care must be monitored on an
ongoing basis (Schuckit, 2016).
Available Knowledge
The Centers for Disease Control and Prevention (CDC) reported that opioids were involved
in 46,000 deaths in the United States in 2018 (Centers for Disease Control and Prevention, 2020).
Synthetic opioids, excluding methadone, were responsible for 31,335 of the reported deaths
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(Centers for Disease Control and Prevention, 2020). The CDC report endorses increasing the
provision of MAT and expanding the distribution of naloxone for overdose reversal (Centers for
Disease Control and Prevention, 2020).
The use of primary care offices as spokes in a treatment program increases access to care
for those seeking treatment. To ease the increasing public health crisis that the opioid epidemic
has evolved into, primary care providers evaluate and treat patients for ongoing care that were
previously seen at specialty clinics. The need for specialty care created a backlog of patients who
sought treatment but were unable to begin without the oversight by an addiction specialty trained
provider. Using the guidelines set forth by the CDC, primary care providers have begun treating
OUD in the primary setting rather than in specialty addiction clinics (Dowell et al., 2016).
In addition, recent legislation, The Substance Use Disorder Prevention that Promotes Opioid
Recovery and Treatment (SUPPORT) for Patients and Communities Act extends the privilege of
prescribing buprenorphine to qualifying practitioners such as nurse practitioners (Congress,
2018).
To prescribe, administer, and dispense buprenorphine to treat opiate use disorder, nurse
practitioner providers are required to complete X-waiver training (U.S. Department of Health
and Human Services, Substance Abuse and Mental Health Services Administration [SAMHSA],
2022). MAT providers who obtain an X-waiver complete required training and education in
regard to best practice standards and the use of evidence-based evaluation and treatment
recommendations to guide practice.
Despite the development of best practice guidelines, some providers still fail to meet the
recommended documentation guidelines (Khalid, et al., 2015). Improving adherence to these
guidelines has proven successful in providing better outcomes for patients (Lasser, et al., 2016;

7
Liebschutz et al., 2017). Using tools and guideline adherence mechanisms increases provider
accuracy and decreases patient dosages of opioids (Liebschutz et al., 2017). Huang et al. (2019)
implemented a five-pronged intervention including 1) creating a patient registry, 2)
standardization of chronic opioid prescribing policies, 3) development of a risk assessment
algorithm, 4) team-based case management, and 5) an electronic health record dashboard. This
five-pronged approach increased the number of appropriate primary care visits and increased the
number of patients on opioid contracts for chronic pain.
Implementation of a quality dashboard to track metrics and monitor quality improvement
provides access to real time information and increases the use of opioid treatment agreements,
urine drug tests, pain and functional assessment questionnaires, and behavioral health visits
(Anderson et al., 2015). Office visits should include informing the patient of risks and harms of
opioid use to ensure that the patient understand the risks/benefits of treatment with opioids
(Dowell et al., 2016). To aid primary care providers in improving the quality of care for patients
with substance use disorder, Providers Clinical Support Systems recommends providers
participate in performance in practice review activities based on American Academy of
Addiction Psychiatry recommendations to identify areas for improvement (AAAP/Providers
Clinical Support Systems, 2019). These activities assess practice according to performance
measures. Additionally, X-waiver training includes a guide to assist a primary care practice in
reviewing its processes for best practices in caring for patients in medically assisted treatment
therapy.
Evidence-based documentation guidelines and clinical quality measures exist to improve
the quality of care for these patients. Adherence to documentation guidelines at one office-based
primary care spoke practice was unknown.
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Project Aims
Global aim: This project sought to evaluate compliance to evidence-based documentation
recommendations for patients being treated with MAT through evaluation of provider
documentation.
Secondary AIM 1: Create a MAT/OUD clinical documentation evaluation tool based on best
practice recommendations by October 2021.
Secondary AIM 2: Audit electronic health records for compliance with best practice
recommendations for clinical documentation and provide audit feedback to X-waivered
providers by February 2022.
Secondary AIM 3: Develop and disseminate recommended changes to current dot phrase for
clinical documentation of best practices by April 2022.
Project Site
The project site is a nurse-practitioner led primary care clinic in New England. This clinic
is affiliated with a state university and employs 8 nurse practitioners and one physician. There
are currently two nurse practitioners at the site who are X-waivered with an active panel of 12
MAT patients. This spoke clinic participates in the hub and spoke program for opioid treatment.
The site provides the community with primary care expertise on diabetes, chronic obstructive
pulmonary disease (COPD), asthma, hypertension, behavioral health, hyperlipidemia, health
promotion and disease prevention, geriatric issues, palliative care, and management of healthrelated transitions in all phases of life. The clinic is designated as a patient-centered medical
home (PCMH) by the Agency for Research and Quality and focuses on comprehensive care for
the whole patient. As a PCMH, the practice has a commitment to continuous quality
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improvement and a patient centered approach to care. Providers at the clinic engage in
performance measurement and outcome improvement activities to improve patient experience.
Methods
A MAT OUD documentation evaluation tool was developed by the project manager based on
recommendations from the American Academy of Addiction Psychiatry /Providers Clinical
Support System Performance Improvement Activity and current best practice guidelines (AAAP
& PCCS, 2019; ASAM, 2020; Liebshcutz et al., 2017; Tanzman & Nalley, 2020) (see Appendix
A). The project team, who consisted of 2 X-waivered NPs and a faculty advisor reviewed and
approved use the audit tool. Patient records were de-identified, and collected de-identified chart
data was stored on a password protected laptop at the clinic. Patient identifiers were not
collected, and records were assigned a chart number at the time reviewed. The tool was pilot
tested by the project manager through review of one de-identified patient record in summer 2021
to ascertain ease of use and time required to complete one chart audit. Each chart audit took
approximately 45 minutes. The sample (n=12) included the electronic health record visit note of
all established active patients who attended an acute visit for MAT medication
management/OUD/opioid dependence in October, 2021. A retrospective review of 100% of the
12 MAT/OUD patient records occurred using the MAT/OUD documentation evaluation tool to
record responses. Provider clinical progress notes and the patient dashboard in the electronic
health record for the month were reviewed and each record required approximately 45 minutes to
review. Raw data findings were recorded on an excel spreadsheet (see Appendix B). Note:
Document is defined as providing reasonable evidence in the chart.
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Data Analysis
Each clinical record represented one progress note and data for one patient for a monthly
clinic visit. Data were reviewed to ascertain whether a metric was present or absent. Mean
difference score values of attainment for documentation metric in the clinical note vs. missing
documentation was computed. Sixteen discrete measurements were analyzed to understand the
overall current state of documentation for patient visits in relation to achievement of
recommended clinical quality measures (see Figure 1 and Figure 2). In addition, the electronic
health record was reviewed for the presence of an annual wellness exam in the past 12 months.
Overall documentation was compliant with evidence-based documentation
recommendations in the majority of documentation elements for patient evaluation and
treatment. Six elements of documentation with room for improvement were identified including
the completion of an annual wellness exam, HIV testing in the past year and status and Hepatitis
C testing in the past year and status, assessment of readiness to change, pregnancy testing for
women of childbearing age, and naloxone rescue kit being offered. Based on these findings, the
current provider note template was revised to recommend inclusion of the missing elements and
incorporate evidence-based recommendations for MAT prescribing documentation. (See
Appendix C). This document was shared with the clinic providers for review and feedback.
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Figure 1. MAT/OUD documentation evaluation tool data. Provider documentation of recommended clinical quality measures in
clinical visit vote and medical record. Note: Document is defined as providing reasonable evidence in the chart.
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Discussion
This project evaluated compliance to evidence-based documentation recommendations
for MAT patients through a chart audit. The purpose of a chart audit is to measure how well
something is being done and to understand if there is room for improvement. The audit
demonstrated consistent documentation of evidence-based documentation recommendations in
the majority of documentation elements.
Six elements of documentation with recommendations for improvement include:
documentation of an annual wellness exam, HIV testing and status. Hepatitis C testing and
status, assessment of readiness to change, pregnancy testing for women of childbearing age, and
naloxone rescue kit and overdose prevention education being offered.
•

Annual exam- The purpose of an annual yearly exam is to prevent illness based
on a patient’s current health status and risk factors. Clinicians should assure that a
current annual examination is documented in medical record before or after
starting or making changes to medication for substance use disorder (ASAM,
2020).

•

HIV screening and status/Hepatitis C (HCV) screening and status- Opioid use has
an increased risk for acquisition and transmission of both HIV and HCV due to
engaging in unsafe behavior (ASAM, 2020; NIDA, 2020). Although opioid use
has an increased risk for acquisition and transmission of HIV and HCV, gaps exist
in HIV/HCV testing among individuals with OUD due to low testing uptake and
testing refusal (Brown, 2019).
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•

Assessing readiness for change- motivational interviewing promotes and
facilitates patient engagement in recovery-oriented activities (ASAM, 2020).
Using tools such as a “readiness ruler” guides conversations about personal
change (Case Western Reserve University Center for Evidence-based Practice,
2022; Moyer, 2009).

•

Pregnancy testing- American College of Obstetrics and Gynecologists (ACOG)
recommends that contraceptive counseling and access to contraceptive services
should be a routine part of substance use disorder treatment among women of
reproductive age to minimize the risk of unplanned pregnancy (ACOG, 2017).

•

Naloxone ordered and overdose prevention education provided- To prevent
overdose, families and patients should be counseled on the development to an
“overdose plan” to share with friends, partners, and/or caregivers. Plan should
include signs of overdose and how to administer naloxone and provide
emergency care. Codes for Screening, Brief Intervention, and Referral to
Treatment (SBIRT) can be used to bill time for counseling a patient about how to
recognize overdose and how to administer naloxone (SAMHSA, 2018).

The results of the chart audit add to the understanding of how evidence-based evaluation
and treatment recommendations are documented in the clinical progress notes by x-waivered
providers. Ongoing review of electronic note templates is recommended to ensure the inclusion
of appropriate elements of evaluation and treatment. Electronic documentation templates help
capture complete and accurate reporting of the clinical encounter. Providers who participate in
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audit and feedback activities and re-design and ongoing review of electronic note templates
improve the clarity and consistency in documentation.
Limitations
Results of this quality improvement project are specific to one primary care clinic in a
rural state. The results cannot be generalized to the population of SUD patients in clinics beyond
this population. The study is limited by a small sample size (n=12) and the review of only one
month’s note as a snapshot. Quality improvement requires several cycles of audit and feedback
to improve processes.
Conclusion
Evidence-based treatment guidelines and screening tools are available to guide providers
in lowering prescription-opioid-related sequelae and eliminating accidental deaths in patients
with substance use disorder. Using tools that promote guideline adherence provide opportunities
to consistently document evidence-based evaluation and treatment recommendations and has
potential to provide better outcomes for patients with substance use disorder. Participation in
audit and feedback of clinical records by providers may improve consistency of behavior.
Providers have a responsibility to participate in the development of best practices and a local
standard of care. Development of a mechanism to audit and monitor best practices provides an
opportunity to identify a performance improvement goal and seek to reach that goal to improve
care processes and ultimately patient outcomes.
Funding
No external funding supported this project.
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Appendix
Appendix A. MAT/OUD Clinical Documentation Evaluation Tool; developed based on American Academy of Addiction Psychiatry
recommended quality metrics (AAAP/Providers Clinical Support Systems, 2019; Tanzman & Nalley, 2020; Williams, et al., 2018)
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Appendix B. MAT/OUD Clinical Documentation Evaluation Tool with Raw Data from Retrospective Chart Review, October 2021.
(AAAP/Providers Clinical Support Systems, 2019; Tanzman & Nalley, 2020; Williams, et al., 2018)
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Appendix C. Recommended updated MAT OUD Template
Patient ID: @NAME@ is a @AGE@ y.o. @SEX@

Subjective:

Chief Complaint: Medication Assisted Treatment Follow-up Office Visit

HPI:

General Health Today?

Any concerns:

Last annual wellness exam?

HIV status? Exposure?

History of hepatitis? Exposure? + Screen?

Any triggers or cravings?

24
If yes, how are you managing them?

Current Medication Assisted Therapy Medications and Dose:

Do you still have your Naloxone and have you received education on using it?

Experiencing any side effects?

Are you currently using any non-prescribed medications or substances?

Psychosocial Check-in:
PHQ-2
In the last two weeks, how often have you felt down, depressed or hopeless?
____ Not at all (0)
____ Several days (1)
____ More than half the days (2)
____ Nearly every day (3)

In the last two weeks, how often have you had little interest or pleasure in doing things?
____ Not at all (0)
____ Several days (1)
____ More than half the days (2)
____ Nearly every day (3)
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Interpretation:
PHQ-2 score obtained by adding score for each question (total points) and ranges from 0-6. A score of 3 is the optimal cutpoint when using the PHQ-2 to
screen for depression. If the score is >3 major depressive disorder is likely. Patients who screen positive should be further evaluated with the PHQ-9, other
diagnostic instruments, or direct interview to determine whether they meet criteria for a depressive disorder.

GAD-2
In the last two weeks, how often have you been bothered by feeling nervous, anxious or on edge?
____ Not at all (0)
____ Several days (1)
____ More than half the days (2)
____ Nearly every day (3)

In the last two weeks, how often have you been bothered by being unable to stop or control worrying?
____ Not at all (0)
____ Several days (1)
____ More than half the days (2)
____ Nearly every day (3)
Interpretation:
GAD-2 score obtained by adding score for each question (total points) and ranges from 0-6. A score of 3 is the preferred cut-off for identifying possible
cases and in which further diagnostic evaluation for generalized anxiety disorder is warranted. Using a cut-off of 3, the GAD-2 has a sensitivity of 86% and
specificity of 83% for diagnosis generalized anxiety disorder.
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Readiness for Change tool
Are you doing any individual therapy/counseling?

If you are doing therapy, who do you see and how often?

Are you participating in any group therapy?

Do you take part in any peer support groups?

Do you have stable housing?

Do you feel safe at home?

Are you currently employed?

Do you have adequate social support?
Do you feel safe in your recovery?
@PROBCOM@
@PSH@
@FAMHX@
@CMEDFASIMPLE@
@ALLERGY@
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@SOCH@
@ROSNH@
Objective:

@VS@
@PHYSICALEXAM@
LABS:
@THISVISIT@
Assessment/Plan:

@NAME@ is a @AGE@ year old with h/o opioid use disorder here for MAT follow-up visit.
@ORDERSDX@
@FOLLOWUP@

Today's face-to-face visit time was *** minutes with *** minutes spent in counseling and/or coordination of care for the problems listed above.
@NPPTEDDONE@
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Author, YEAR

Anderson, D., et al
(2015).
https://doi.org/10.1
097/AJP.0000000
000000177

Dowell, D., et
al.(2016).
https://doi.org/10
.15585/mmwr.rr6
501e1

Purpose/Objective

Design

Sample/Setting

To evaluate the
impact of a clinical
dashboard for
opioid analgesic
management on
opioid prescribing
and adherence to
opioid practice
guidelines in
primary care.

Qualitativ
e Study
Design

Community
Health Center
Inc. (CHCI) is a
multisite FQHC
in Connecticut
providing
comprehensive
primary care
services for over
140,000
medically
underserved
patients.

CDC Guideline for
Prescribing Opioids
for Chronic Pain United States, 2016

Practice
guidelines

This guideline
provides
recommendatio
ns for primary
care clinicians
who are
prescribing
opioids for
chronic pain
outside of active
cancer
treatment,
palliative care,
and end-of-life
care.

Measurement
Outcomes
During the year before
implementation 1309
patients had received
COT or 3.4% of all
CHCI patients aged 18
years and above with
at least 1 medical
primary care visit
during that year
compared with 1270
patients or 3.1% of all
CHCI adult patients
with at least 1 medical
primary care visit in
the post
implementation year.
The guideline
addresses 1) when to
initiate or continue
opioids for chronic
pain; 2) opioid
selection, dosage,
duration, follow-up,
and discontinuation;
and 3) assessing risk
and addressing harms
of opioid use. CDC
developed the
guideline using the
Grading of
Recommendations
Assessment,
Development, and
Evaluation (GRADE)

Analysis and
Findings
77% of PCPs felt
that the
dashboard was
clinically useful.
Implementation
of the dashboard
was associated
with an increase
in the use of
OTAs, UDTs, pain
and functional
assessment
questionnaires,
and behavioral
health visits.
CDC obtained
input from
experts,
stakeholders, the
public, peer
reviewers, and a
federally
chartered
advisory
committee

Limitations and
conclusions
Lack of a control group
limits the ability to
assert causality between
the implementation of
the dashboard and the
changes observed in
guideline adherence.
Addition of intermittent
opioid user from the 90
day user group.
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Level of Evidence

JHNEBP Evidence Tool

Level 3

http://www.cdc.gov/dru
goverdose/prescribingre
sources.html

Grade A
JHNEBP Evidence Tool

Level 4

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Huang, K., et al.
(2019).
https://doi.org/10
.5055/jom.2019.0
535

A multicomponent
intervention to
improve adherence
to opioid
prescribing and
monitoring
guidelines in
primary care.

Qualitativ
e Study

Primary care
practice
affiliated with a
tertiary care
hospital in
Boston serving
over 40,000
patients and
employing 35
PCPs.

Measurement
Outcomes
framework, and
recommendations are
made on the basis of a
systematic review of
the scientific evidence
while considering
benefits and harms,
values and
preferences, and
resource allocation.
The team
implemented a fivepronged intervention.
1.
Creating a
patient registry
2.
Standardizatio
n of chronic opioid
prescribing policies
3.
Development
of a risk-assessment
algorithm
4.
Team-based
case management
5.
EHR
dashboard

Analysis and
Findings

Limitations and
conclusions

Level of Evidence

The percentage
of patients
chronically
prescribed
opioids in the
practice
decreased from
1.6 percent (n =
519) in
September 2015
to 1.3 percent (n
= 480) in
September 2016.
Of the patients
who stopped
receiving
prescription
opioids from our
practice during

The single practice
design limits
generalizability to
practices with several
locations. During the
course of the
intervention,
Massachusetts passed a
law requiring providers
to check the PMP every
time opioids were
prescribed, and this
likely contributed to the
increased rate of PMP
usage. We therefore
cannot assume all
changes in opioid
prescribing were
associated with the

JHNEBP Evidence Tool

Level 3

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Analysis and
Findings
this time period,
the largest
proportion (38
percent) had
been weaned off
due to symptom
control via other
modalities,
patient
preference, or
resolution of
pain. The second
largest
proportion (21
percent) was
terminated due
to pain
agreement
violations. The
remaining
patients were no
longer a patient
at our practice
(17 percent),
were now
receiving opioid
medication from
another provider
(7 percent), or

Limitations and
conclusions
systematic changes we
implemented. However,
there were no
concurrent
interventions in our
practice that may have
influenced opioid
prescribing practices.
Lastly, clinicians may
have been adhering to
some guidelines preintervention, but
without a structured
field in the EHR to
automatically document
these practices, they
were not uniformly
captured beforehand.

Level of Evidence
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Analysis and
Findings
were deceased (5
percent) from
nonopioid
related
etiologies.
The percentage
of patients on
chronic opioid
therapy with no
primary care visit
in the past year
decreased from 9
to 0.2 percent (p
< 0.0001). The
percentage of
patients on
chronic opioid
therapy who had
signed a
controlled
substances
agreement in the
past year
increased from
46 percent at
baseline to 76
percent a year
after program

Limitations and
conclusions

Level of Evidence
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Author, YEAR

Purpose/Objective

Design

Kay, C., et al
(2016).
https://doi.org/10
.5055/jom.2016.0
350

Adherence to
chronic opioid
therapy prescribing
guidelines in a
primary care clinic.
Journal of opioid
management,
12(5), 333–345.

Retrospec
tive chart
review

Sample/Setting

Measurement
Outcomes

Analysis and
Findings
implementation
(p < 0.0001).
The clinic had
Adults
Patient
834 (9 percent)
prescribed
demographics,
patients on
chronic opioids medical diagnoses,
chronic opioids,
(three or more tobacco status,
with 335 on a
monthly
provider status,
pain agreement.
prescriptions
documentation of
Documentation
within a year)
guidelineof opioidfor CNCP
recommended
monitoring
between April
opioid-monitoring
practices was
1, 2014 and
practices, pain
lacking. Logistic
April 1, 2015.
agreement status,
regression
indicated that
and opioid
patients were
prescription.
significantly
Univariate statistics
were used to explore more likely to be
on an agreement
differences in
if they were
patient
Caucasian
demographics,
(adjusted odds
comorbidities, and
ratio [OR] 2.17
guideline[95% CI 1.41,
recommended
3.39]), had a
opioid-monitoring
baseline urine
practices by chronic drug screen
(adjusted OR
pain and pain
10.72 [95% CI
agreement status.

Limitations and
conclusions

Level of Evidence

Limitations:
Full article unavailable
– does not state where
study took place. Data
table and results
unavailable to be
reviewed except for
excerpts from
pubmed/source
Journal

Unable to determine
based on pubmed
information.
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Khalid, L., et al
(2015).
https://doi.org/10
.1111/pme.12602

Adherence to
prescription opioid
monitoring
guidelines among
residents and
attending
physicians in the
primary care
setting. Pain
medicine (Malden,
Mass.), 16(3), 480–
487

Retrospec
tive Cross
sectional
study

Large primary
care practice at
a safety net
hospital in
New England.
18-99 yo
patients with
long-term
opioid
treatment for
chronic
noncancer pain

The primary
outcomes were
adherence to any
one of two American
Pain Society
Guidelines by
residents and
attendings: (1)
documentation of at
least one opioid
agreement
(contract) ever and
(2) any urine drug
testing in the past
year, and evidence

Analysis and
Findings
6.16, 19.41]),
were prescribed
a schedule II
controlled
medication
(adjusted OR
11.92 [95% CI
6.93, 21.62]), and
had risk assessed
to some degree
(adjusted OR
3.06 [95% CI
1.90, 4.96]).
Similar
proportions of
resident and
attending
patients had a
controlled
substance
agreement
(45.1% of
resident patients
vs. 42.4% of
attending
patient, P = 0.47)
or urine drug
testing (58.6% of
resident patients

Limitations and
conclusions

Level of Evidence

With some variability,
residents and
attending physicians
were only partly
compliant with
national guidelines.
Residents were more
likely to manage
patients with a higher
likelihood of opioid
misuse.
Limitations: Data were
abstracted from the
EMR and therefore
mental health, tobacco

JHNEBP Evidence Tool

Level 2

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes
of potential
prescription misuse
defined as ≥2 early
refills.

Krebs, E. et al.
(2018).

Effect of Opioid vs
Nonopioid

RCT

Patients were
recruited from

Eligible patients had
moderate to severe

Analysis and
Findings
vs. 63.6% of
attending
patients, P =
0.16). Resident
patients were
more likely to
have two or
more early refills
in the past year
relative to
attending
patients (42.8%
vs. 32.5%; P =
0.004). In the
adjusted
regression
analysis, resident
patients were
more likely to
receive early
refills (odds ratio
1.82, 95%
confidence
interval 1.262.62) than
attending
patients.
There was no
significant

Limitations and
conclusions
use, alcohol use and
substance use disorders
were derived from
billing information or
ICD codes, which may
be incomplete or
unreliable. We did not
have information about
early refills provided by
prescribers outside of
the primary care
practice. Thus, the
prevalence of early
refills in our study is
likely an underestimate.

Level of Evidence

Treatment with opioids
was not superior to

JHNEBP Evidence Tool
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Author, YEAR

Purpose/Objective

https://doi.org/10
.1001/jama.2018.
0899

Medications on
Pain-Related
Function in
Patients With
Chronic Back Pain
or Hip or Knee
Osteoarthritis Pain:
The SPACE
Randomized
Clinical Trial.

Design

Sample/Setting
Veterans Affairs
primary care
clinics from June
2013 through
December 2015;
follow-up was
completed
December 2016.

Measurement
Outcomes
chronic back pain or
hip or knee
osteoarthritis pain
despite analgesic use.
Of 265 patients
enrolled, 25 withdrew
prior to randomization
and 240 were
randomized.

Analysis and
Findings
difference in
pain-related
function
between the 2
groups over 12
months

Limitations and
conclusions
treatment with
nonopioid medications
for improving painrelated function over 12
months. Results do not
support initiation of
opioid therapy for
moderate to severe
chronic back pain or hip
or knee osteoarthritis
pain.
Limits:
Because primary
outcomes were patientreported, results are
subject to potential
reporting bias that
would likely favor
opioids. Second, there
was an imbalance in
prerandomization
treatment preference.
Any effect of this
imbalance would likely
favor opioids. Third,
because this study was
conducted in VA clinics,
patient characteristics
differ from those of the

Level of Evidence

Level 1

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Kroenke, K., et al
(2014).
https://doi.org/10
.1001/jama.2014.
7689

Telecare
collaborative
management of
chronic pain in
primary care: a
randomized clinical
trial.

RCT

Patients were
enrolled from 5
primary care
clinics in a single
Veterans Affairs
medical center
from June 2010
through May
2012, with 12month followup completed
by June 2013.

Patients were
randomized either to
an intervention group
(n = 124) or to a usual
care group whose
members received all
pain care as usual
from their primary
care physicians
(n = 126). The
intervention group
received 12 months of
telecare management
that coupled
automated symptom
monitoring with an
algorithm-guided
stepped care

Analysis and
Findings

Limitations and
conclusions
general population,
most notably in sex
distribution. Fourth,
patients with
physiological opioid
dependence due to
ongoing opioid use
were excluded, so
results do not apply to
this population.
Overall, mean
Limitations:
(SD) baseline BPI 1) The sample consists
scores in the
of veterans from a
intervention and single center. 2) Many
control groups
patients had pain for
were 5.31 (1.81)
years that involved at
and 5.12 (1.80),
least several bodily
respectively.
sites. 3) The comparator
Compared with
group was usual care
usual care, the
rather than an attention
intervention
control; thus, the
group had a 1.02- relative effects of
point lower (95% optimizing analgesics,
CI, −1.58 to
automated monitoring,
−0.47) BPI score
and nurse contacts
at 12 months
cannot be unbundled. 4)
(3.57 vs 4.59).
Not have data on
Patients in the
medications prescribed
intervention
outside of the Veterans

Level of Evidence

JHNEBP Evidence Tool

Level 1

Grade B
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Author, YEAR

Lasser, et al
(2016).
https://doi.org/10
.1016/j.jsat.2015.
06.018

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes
approach to
optimizing analgesics.

A multicomponent
intervention to
improve primary
care provider
adherence to
chronic opioid
therapy guidelines
and reduce opioid
misuse: a cluster
randomized
controlled trial
protocol

RCT

53 PCPs from
three Bostonarea community
health centers
and one urban
safety-net
hospital-based
primary care
practice who
have at least
four patients
meeting
inclusion criteria

PCPs were
randomized to receive
the intervention,
which includes four
components: 1) nurse
care management, 2)
use of a patient
registry, 3) academic
detailing, and 4)
electronic tools, or a
control condition,
which includes only

Analysis and
Findings
group were
nearly twice as
likely to report at
least a 30%
improvement in
their pain score
by 12 months
(51.7% vs 27.1%;
relative risk, 1.9
[95% CI, 1.4 to
2.7]), with a
number needed
to treat of 4.1
(95% CI, 3.0 to
6.4) for a 30%
improvement.
Starting in July
2013, we piloted
the intervention
for five months
with two PCPs
and their 33
patients on
chronic opioid
therapy at the
urban safety-net
hospital based
practice. In this
initial pilot test,

Limitations and
conclusions
Affairs system. 5) The
trial did not include a
formal cost analysis.

Level of Evidence

It is not possible to
determine the individual
effect of each
intervention component
on quantitative study
outcomes. Rather, we
are only able to test the
effectiveness of the
entire, four-component
intervention package
against the electronic
tools-only control
condition.

JHNEBP Evidence Tool

Level 1

Grade C
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes
the use of the
electronic tools.

Analysis and
Findings
we
demonstrated
feasibility and
acceptability; the
intervention was
well received by
the PCPs and
patients. We
observed a high
frequency of
aberrant
behaviors among
patients, with
four of 33
patients having
one of the
following
aberrant
behaviors: they
had incorrect
numbers of
opioid pills at pill
counts with
NCMs, had
Tylenol in their
opioid pill bottles
instead of the
prescribed
opioid, cocaine

Limitations and
conclusions

Level of Evidence
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Liebschutz, , et al
(2017)
https://doi.org/10
.1001/jamaintern
med.2017.2468

Improving
Adherence to Longterm Opioid
Therapy Guidelines
to Reduce Opioid
Misuse in Primary
Care: A ClusterRandomized
Clinical Trial

Cluster
RCT

53 primary care
clinicians (PCCs)
and their 985
patients
receiving longterm opioid
therapy for pain

Intervention PCCs
received nurse care
management, an
electronic registry, 1on-1 academic
detailing, and
electronic decision
tools for safe opioid
prescribing. Control
PCCs received
electronic decision
tools only.

Analysis and
Findings
on urine drug
screens, and
were not taking
medication as
prescribed.
At 1 year,
intervention
patients were
more likely than
controls to
receive
guidelineconcordant care,
to have a
patient-PCC
agreement, and
to undergo at
least 1 UDT.
There was no
difference in
odds of early
refill receipt
between groups.
Intervention
patients were
more likely than
controls to have
either a 10%
dose reduction

Limitations and
conclusions

Level of Evidence

Solely used EHR and did
not capture patient
experience of the
intervention, including
its potential impact on
pain control, function,
and disability.
Furthermore, EHR data
do not provide accurate
substance use and
mental health
diagnoses. Also lacks
ability to measure
opioid prescribing
outside of these
practices (multifacility
prescriptions)

JHNEBP Evidence Tool

Level 2

Grade A
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Manchikanti, L., et
al. (2017)

Responsible, Safe,
and Effective
Prescription of
Opioids for Chronic
Non-Cancer Pain:
American Society
of Interventional
Pain Physicians
(ASIPP) Guidelines.
Pain physician.

Practice
Guidelines
-

In preparation
of the current
guidelines, we
have focused on
the means to
reduce the
abuse and
diversion of
opioids without
jeopardizing
access for those
patients
suffering from
non-cancer pain
who have an
appropriate
medical
indication for
opioid use.

These guidelines are
intended to provide a
systematic and
standardized
approach to this
complex and difficult
arena of practice,
while recognizing that
every clinical situation
is unique.

Analysis and
Findings
or opioid
treatment
discontinuation.
In adjusted
analyses,
intervention
patients had a
mean mg lower
than controls
These guidelines
were developed
based on
comprehensive
review of the
literature,
consensus
among the
panelists, in
consonance with
patient
preferences,
shared decisionmaking, and
practice patterns
with limited
evidence, based
on randomized
controlled trials
(RCTs) to

Limitations and
conclusions

Level of Evidence

Conclusions: Chronic

JHNEBP Evidence Tool

opioid therapy should
be provided only to
patients with proven
medical necessity and
stability with
improvement in pain
and function,
independently or in
conjunction with other
modalities of
treatments in low
doses with appropriate
adherence monitoring
and understanding of
adverse events.

Level 4

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Parchman, M. L.,
et al. (2017).
https://doi.org/10
.3122/jabfm.2017.
01.160183

Primary Care Clinic
Re-Design for
Prescription Opioid
Management.
Journal of the
American Board of
Family Medicine :
JABFM, 30(1), 44–
51.

Quality
Improvem
ent
Redesign

Thirty primary
care clinics
across the
United States
selected for
their use of
team-based
workforce
innovations.

Site visits included
interviews with
leadership, clinic
tours, observations of
clinic processes and
team meetings, and
interviews with staff
and clinicians. Data
were reviewed to
identify common
attributes of clinic
system changes
around chronic opioid
therapy (COT)
management. These
concepts were
reviewed to develop
narrative descriptions
of key components of
changes made to
improve COT use.

Analysis and
Findings
improve pain and
function in
chronic noncancer pain on a
long-term basis.
Twenty of the
thirty sites had
addressed
improvements in
COT prescribing.
Across these
sites a common
set of 6 Building
Blocks were
identified: 1)
providing
leadership
support; 2)
revising and
aligning clinic
policies, patient
agreements
(contracts) and
workflows; 3)
implementing a
registry tracking
system; 4)
conducting
planned, patient-

Limitations and
conclusions

Level of Evidence

The practical steps and
strategies represented
in the 6 Building Blocks
were used by innovative
clinics to address the
use of COT in their
patient population and
should be considered in
designing improvement
initiatives in other
primary care settings. It
is important to note,
however, that these
new guidelines and the
associated workflow
redesigns to implement
them cause burdens of
their own. Unless they
can be demonstrated to
significantly improve
patient outcomes, while
also decreasing provider
and staff burnout, there
may be resistance to

JHNEBP Evidence Tool

Level 3

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Quanbeck, A., et
al (2018).
https://doi.org/10
.1186/s13012018-0713-1

A randomized
matched-pairs
study of feasibility,
acceptability, and
effectiveness of
systems
consultation: a
novel
implementation
strategy for
adopting clinical

Observati
onal
Prospectiv
e Case
Control

The study took
place in family
medicine clinics
that are part of
UWHealth, the
health system
affiliated with
the University of
Wisconsin
Department of
Family Medicine

Measurement
Outcomes

Analysis and
Findings
centered visits;
5) identifying
resources for
complex
patients; and 6)
measuring
progress toward
achieving clinic
objectives.
Common
components of
clinic policies,
patient
agreements and
data tracked in
registries to
assess progress
are described.
This pilot test of
The systems
systems consultation
consultation
used the RE-AIM
implementation
(Reach, Effectiveness, strategy
Adoption,
demonstrated
Implementation,
feasibility,
Maintenance)
acceptability, and
evaluation framework. effectiveness in a
To assess reach, we
study of eight
compared
primary care
characteristics of
clinics. Clinic

Limitations and
conclusions
implementation. In
addition, primary care
clinics alone cannot
stem the tide of opioid
overuse within local
communities; it will
require communitywide initiatives that
include all prescribers.

Level of Evidence

The problem of opioid
prescribing received
attention both locally
and nationally during
the intervention period,
and notable secular
changes in opioid
prescribing outcomes
were evident. The
UWHealth system also
introduced a new

JHNEBP Evidence Tool

Level 3

Grade B/C
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Author, YEAR

Purpose/Objective
guidelines for
Opioid prescribing
in primary care.
Implementation
science

Design

Sample/Setting
and Community
Health. The
intervention
was introduced
to the four
intervention
clinics on
staggered
starting dates

Measurement
Outcomes
intervention clinics,
control clinics, and
clinics that refused
participation,
including number of
prescribers and
characteristics of the
patient panel. For
effectiveness, we
examined overall
opioid prescribing
rates; average
morphine-equivalent
daily dose for patients
on long-term opioid
therapy. For adoption,
we examined the
characteristics of clinic
change teams,
attendance at
scheduled
intervention activities,
and ratings by staff
participants on a
satisfaction survey.
Assessment of
implementation
focused on the cost of
delivering the

Analysis and
Findings
teams actively
participated in
the intervention
(attendance at
scheduled
implementation
activities was
83% of
consented staff
members) and
reported positive
feedback in focus
groups and
satisfaction
surveys.

Limitations and
conclusions
opioid-prescribing policy
in February 2016,
concurrent with the
beginning of the study
period. The Centers for
Disease Control and
Prevention published
guidelines for opioid
prescribing in March
2016 that are based on
the guidelines [24] used
in this study.

Level of Evidence
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Saffore, C. D, et al.
(2020).
https://doi.org/10
.3399/bjgp20X711
737

Identification of
barriers to safe
opioid prescribing
in primary care: a
qualitative analysis
of field notes
collected through
academic detailing

Qualitativ
e Analysis

June 2018 to
August 2018 to
licensed PCPs
with
prescriptive
authority within
a large
independent
health system in
the Chicago
area.

Measurement
Outcomes
implementation
strategy.
Maintenance was
assessed using 6month follow-up data
on the effectiveness
measures described
above.
Intervention involved
visits by trained
detailers to PCPs who
contemporaneously
documented details
from each visit via
field notes. Using
qualitative analysis,
field notes were
analyzed to identify
recurring themes
related to opioid
prescribing barriers.

Analysis and
Findings

Limitations and
conclusions

Level of Evidence

Detailer-entered
field notes from
186 AD visits
with PCPs were
analyzed.
Barriers to safe
opioid
prescribing were
organized into six
themes: 1) gaps
in knowledge; 2)
lack of
prescription
monitoring
program (PMP)
utilization; 3)
patient pressures
to prescribe
opioids; 4)
insurance
coverage

Barriers to safe opioid
prescribing in primary
care, identified through
AD visits among this
large group of PCPs.
Over 75% of PCPs
indicated at least 1
barier, 50% indicated at
least 2 barriers and 19%
indicated at least 3
barriers.

JHNEBP Evidence Tool

Level 3

Grade C
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Seal, K. et al
(2019).
https://doi.org/10
.1016/j.cct.2018.1
2.006

Optimizing pain
treatment
interventions
(OPTI): A pilot
randomized
controlled trial of
collaborative care
to improve chronic
pain management
and opioid safetyRationale,
methods, and
lessons learned.

RCT

San Francisco
VA Health Care
System trail
enrolling 100
veterans

Measurement
Outcomes

Analysis and
Findings
policies; 5)
provider beliefs;
and 6) health
system pain
management
practices.
A primary endpoint
Overall, 90
for this pilot study was participants (90%
increased self-efficacy of those
among PCPs and the
enrolled)
Care Managers in cocompleted the
creating and
trial and all study
encouraging the use
assessments.
of SMART goals
captured in the Pain
Care Plans with
participants, since this
formed the
foundation for both
the Collaborative Care
and Attention Control
conditions.

Limitations and
conclusions

Level of Evidence

First, the study was
JHNEBP Evidence Tool
implemented during
their primary care clinics
and they reported
difficulties obtaining
Level 2
approval for and
scheduling one-hour
research study visits
Grade C
between regularly
scheduled 30-minute
patient visits. Second,
despite training on
Shared Decision-Making
in which PCPs elicited
participants’ values and
goals in order to
construct SMART goals
to develop the Pain Care
Plan, some PCPs found it
challenging to
accomplish this task
within the initial 60minute visit, which also
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Analysis and
Findings

Limitations and
conclusions
included detailed
assessment and
education about chronic
pain and opioid safety.
PCPs reported that
some patients had
difficulty articulating life
values and goals and/or
constructing “SMART”
goals that were specific,
measurable, actionoriented, etc. Third,
study PCPs reported
varying degrees of role
confusion regarding
their relationship with
the participant’s own
PCP when it came to
making changes to
patients’ pain regimens
in accordance with the
Pain Care Plans. Finally,
study PCPs found it
difficult to make
referrals for nonpharmacological pain
management services,
especially
complimentary and

Level of Evidence
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Analysis and
Findings

Limitations and
conclusions
integrative health
services in VA (because
of a dearth of services)
as well as in the
community (because of
limited resources or
prohibitive costs to
veterans). As the study
progressed, study PCPs
were strongly
encouraged to assist
participants in
developing more selfdirected SMART goals.
Examples of selfdirected goals are
walking, meditating at
home or engaging in
pleasurable activities; in
other words, activities
that align with
participants’ values,
shift attention away
from chronic pain to
more enjoyable
activities and rely less
on referrals to VA or
community resources.

Level of Evidence
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Purpose/Objective

Design

Sample/Setting

Weller L. M.
(2020).
https://doi.org/10
.1097/JXX.000000
0000000487

Development and
implementation of
a primary care
clinic workflow
protocol to meet
opioid prescribing
guidelines.

Quality
improvem
ent
project
using an
education
al
interventi
on was
implemen
ted

Ten Washington
State primary
care clinics

Measurement
Outcomes
Primary care clinics
viewed the project's
instructional
YouTube webinar
that explained the
project's primary
care clinic workflow
protocol, opioid
prescribing best
practice guidelines,
and the
organization's
mandated EMR
charting for chronic
pain management.

Analysis and
Findings
Preintervention
and
postintervention
measures, which
included five
different
documented
patient
completion rates
of the
organization's
best practices for
opioid
prescribing, were
used to assess
for improvement
to guideline
adherence.
Additionally,
participants
completed a
questionnaire
regarding their
perceptions of
the webinar as
an educational
tool.

Limitations and
conclusions
Postintervention data
showed significantly (p ≤
.05) increased
completion rates for
three of five outcome
measures, indicating
improvement in
guideline adherence.
Limitations:
Generalizability, study
was limited to ten
Washington clinics. The
study also utilized
YouTube educational
materials which may not
be an effective form of
teaching for some
providers. Only
addressed 5 areas of
documentation.

Level of Evidence
JHNEBP Evidence Tool

Level 3

Grade B
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Purpose/Objective

Design

Sample/Setting

Witt et al, 2018

To describe the
steps taken and
results obtained by
a rural primary
care practice to
effectively
implement opioid
prescribing
guidelines.

Qualitativ
e Study
Design

435 patients –
Mayo Clinic
health setting

Measurement
Outcomes
Between December 1,
2014, and May 30,
2017, a quality
improvement project
was undertaken.
Elements included
prescribing registries,
a nurse coordinator,
and an Opioid Use
Review Panel. Clinic
workflow was
redesigned to more
consistently
incorporate these and
other guideline
recommendations
into practice. The
effect on opioid
prescribing was
measured as well as
patient outcomes.

Analysis and
Findings
Of the remaining
435 patients, 96
(22.1%; 95% CI,
18.4-26.2) had
decreased
prescribing
below the
threshold for
inclusion or were
no longer
receiving opioid
prescriptions.
Originally, 64
patients (13.9%;
95% CI, 11.017.3) were using
average daily
doses equal to or
greater than 90
morphine
milligram
equivalents.
After
implementation,
54 of 435
patients (12.4%;
95% CI, 9.6-15.8)
were still using
equal to or

Limitations and
conclusions
Estimates for patients’
decrease in use, in the
absence of or before
such a program’s
implementation, have
not been well studied,
so it is difficult to fully
quantify the effects of
this project.
Data outcomes are
currently available only
in aggregate. This limits
the type of analyses that
can be performed (eg,
unable to determine for
most patients whether
they had different
starting vs ending use
categories, unknown
follow-up time per
patient, and only
presence or absence
during the second
phase) and the
conclusions that can be
drawn. For example,
although the number of
patients using greater
than 90 MME/D

Level of Evidence
JHNEBP Evidence Tool

Level 3

Grade B
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Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes

Zgierska, A. E., et
al (2020).
https://doi.org/10
.1186/s12875020-01320-9

Increasing systemwide
implementation of
opioid prescribing
guidelines in
primary care:
findings from a
non-randomized
stepped-wedge
quality
improvement
project.

Quality
Improvem
ent
Project

The academic
health system in
Wisconsin, USA
included 35
primary care.
The first 9
consenting
clinics
(convenience
sample) were
enrolled into a
non-randomized
stepped-wedge
QI project.

The QI participants
were volunteer clinical
staff (prescribers,
nurses and others) at
each intervention
clinic. The evaluation
subjects (target
patient population)
were identified by the
search of EHR-based
data from the
problem list,
encounter, and billing
records, using the
health systemdeveloped criteria:
age ≥ 18 years old;
active-patient status
(seen at the clinic in
the past 3 years);
primary care provider

Analysis and
Findings
greater than 90
morphine
milligram
equivalents per
day after
accounting for
death or loss to
follow-up.
A total of 215
unique health
care providers,
including 73
prescribers and
142 other clinic
staff from the
enrolled 4 family
medicine and 5
internal medicine
clinics completed
at least one
component of
the QI
intervention (QI
participants;
Table 1). Among
the QI
participants,
48.4% completed
half or more of

Limitations and
conclusions
decreased, it is
unknown whether they
are not present in the
greater than 90 MME/D
group due to decreased
usage, death, or loss to
follow-up.

Level of Evidence

Augmenting routine
policy implementation
with targeted QI
intervention, delivered
to volunteer clinic staff,
did not additionally
improve clinic-level,
opioid guidelineconcordant care
metrics. However, the
observed effect sizes
suggested this approach
may be effective,
especially in higher-risk
patients, if broadly
implemented.

JHNEBP Evidence Tool

Level 3

Grade B
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Author, YEAR

Purpose/Objective

Design

Sample/Setting

Measurement
Outcomes
within the health
system; no diagnosis
of malignant
neoplasm (except
non-melanoma skin
cancer) or palliative or
hospice care status;
and meeting at least
one of the two
criteria: 1) ≥1 opioid
prescription issued in
the prior 45 days
and ≥ 3 opioid
prescriptions issued in
the prior 4 months; or
2) ≥1 opioid
prescription issued in
the prior 45 days, and
presence of a chronic
pain diagnosis and a
controlled substance
agreement.

Analysis and
Findings
the intervention
components;
44.7% completed
at least 4 of the 6
in-person
practice
facilitation
sessions; 31.2%
completed the
opioid
prescribing and
23.2% completed
the shared
decision making
online modules

Limitations and
conclusions

Level of Evidence

